London regulatory news service (RNS) notices published this week highlighted several developments in the natural-resources and life-sciences sectors, including a construction update from African-focused miner Pensana, preclinical and trial-design disclosures from biotech Avacta Therapeutics, and a brief mention that Ajax (AQSE: AJAX), the natural-resources investment company, has agreed an extension — though the RNS item provided no further particulars.
Progress at Pensana’s Longonjo site
Pensana said in its RNS that construction work at the Longonjo magnet rare-earth mine in Angola is now “over 30% complete.” The company followed up on an earlier notice concerning a US$165-million investment in the Cascade project with backing from the State of Qatar and confirmed that it had received a US$15-million tranche to date.
The RNS said Pensana is continuing engagement with Cascade and its backers while it has also entered detailed financing discussions with its major shareholders. The company said it has held successful detailed negotiations with potential major offtake partners and intends to enter into offtake agreements to support debt facilities with ABSA and EXIM when required. Pensana added it will keep stakeholders informed as financing and mine development progress.
Avacta presents FOCUS-01 design at AACR
Separately, Avacta Therapeutics used an RNS to announce the presentation of the FOCUS-01 trial design and supporting preclinical data for AVA6103 (FAP‑Exd), a next‑generation peptide‑drug conjugate targeted at pancreatic ductal adenocarcinoma (PDAC). The material was presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer in San Diego, held 25–28 September 2026.
Avacta described FOCUS‑01 as a Phase I trial for its AVA6103 candidate. The company framed the programme as its first Next‑Generation pre|CISION® peptide‑drug conjugate (PDC). The RNS underlined the potential of AVA6103 in PDAC based on the preclinical package and said the trial design details had been shared at the AACR conference.
Ajax (AQSE: AJAX) — extension announced, details limited
The RNS hotlist item also referenced Ajax [AQSE: AJAX], identified as a natural-resources investment company, indicating the company had “agreed an extension” but the notice was truncated and offered no further information on the nature, duration or parties to that extension. The limited language in the hotlist means investors and other interested parties must await a formal, complete RNS from Ajax for further specifics.
“The RNS hotlist referenced Ajax agreeing an extension, but the published extract was incomplete and gave no further particulars.”
Until Ajax issues a full RNS with the necessary details, market participants should treat the brief reference as a placeholder rather than a fully formed disclosure.
- Pensana: Longonjo construction >30% complete; US$15m received of US$165m Cascade investment; financing and offtake discussions ongoing.
- Avacta: Presented FOCUS-01 Phase I trial design for AVA6103 at AACR; preclinical data highlighted.
- Ajax (AQSE: AJAX): Announced an extension in the RNS hotlist, but the extract lacks detail — further information pending.
| Company | Headline update | Key figure |
|---|---|---|
| Pensana | Construction progress, financing discussions | 30% complete; US$15m received |
| Avacta | FOCUS‑01 trial design presented | Phase I trial; AACR presentation |
| Ajax (AQSE: AJAX) | Extension announced (details pending) | Not specified |
Local investors in Ajax‑listed securities and residents with an interest in the mining and life‑sciences sectors should note two practical consequences. First, for Pensana, the financing pathway — including planned offtake agreements and debt facilities with ABSA and EXIM — will be material to the pace of construction and the timeline to commissioning at Longonjo. Second, for Avacta, early clinical trial design and preclinical disclosures can influence investor sentiment around prospectively high‑risk, high‑reward oncology programmes.
For Ajax (AQSE: AJAX), the immediate priority for stakeholders is a complete RNS. The brief mention in the hotlist signals corporate activity but does not meet the level of disclosure needed for market participants to assess its significance. WE NEWS will monitor filings and publish a follow‑up when Ajax issues a substantive notice.
